正在加载公司
Just reported
From Citius Oncology's results release of 2026年10月26日; its quarterly report has since been filed.
Actual
US$1.5M
-10% q/q
Guided
—
No guide given
Actual
-US$0.08
Guided
—
No guide given
Actual
-US$8.7M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Citius Oncology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$33.5BA
NBIXNeurocrine Biosciences, Inc.US$17.6BA+
ELANElanco Animal Health IncorporatedUS$13.2BA
KNSAKiniksa Pharmaceuticals International, plcUS$8.1BA+
LQDALiquidia CorporationUS$5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A基于 Citius Oncology, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
Not rated
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
Citius Oncology, Inc. 目前还没有可绘制的评级历史。季度评级只用当时已公开的申报文件重建，而这家公司披露的还不足以评出哪怕一个季度。
